Current treatment for CHB is effective in suppressing HBV replication and preventing adverse outcomes; however, these treatments are not curative.25 Professional societies have established guideline criteria for treatment largely based on cirrhosis, HBV DNA levels, and ALT levels.26,27,28 This study noted that African American or Black participants had a lower prevalence of HBeAg and lower HBV DNA levels among those who were HBeAg-negative, leading to a lower percentage meeting treatment criteria. The gene discussed is GPT; the disease is Cirrhosis.